Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Female × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 57 Sarcoma 6 Squamous Cell Carcinoma of Head and Neck 5 Ovarian Neoplasms 5 Neoplasms 5 Neoplasm Metastasis 5 Sarcoma, Ewing 4 Lymphoma, Non-Hodgkin 4 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Osteosarcoma 3 Neuroblastoma 3 Multiple Myeloma 3 Medulloblastoma 3 Glioma 3 Carcinoma, Non-Small-Cell Lung 3 Wilms Tumor 2 Prostatic Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Melanoma 2 Lymphoma 2 Liposarcoma 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Head and Neck Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Ependymoma 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2

Interventions

Tamoxifen 2 Paclitaxel 2 pyrotinib 1 pembrolizumab 1 palbociclib 1 iniparib 1 darolutamide 1 Thioctic Acid 1 Pentoxifylline 1 Metformin 1 Doxorubicin 1 Cyclophosphamide 1 Capecitabine 1 Aromatase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03065621 2023-04-19

NeoRHEA

Jules Bordet Institute

Phase 2 Completed

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡